ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario.
ECOG – Eastern Cooperative Oncology Group
FISH – fluorescence in situ hybridisation
IHC – immunohistochemistry
NSCLC – non small cell lung cancer
OS – overall survival
PFS – progression-free survival;
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
02
2022
entrez:
8
9
2022
pubmed:
9
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Anaplastic lymphoma kinase (ALK) inhibitors have shown significant efficacy in ALK -rearranged non-small cell lung cancer (NSCLC) patients with good performance status (PS) in multiple randomised studies. However, there is limited data on patients with poor performance status. We carried out a retrospective analysis of prospectively collected data of patients with ALK-rearranged NSCLC and Eastern Cooperative Oncology Group (ECOG) PS of 2-4 treated at a single academic cancer centre from January 2013 to November 2018. The outcomes, progression-free survival (PFS) and overall survival (OS) were calculated from the date of diagnosis. SPSS version 20 was used for all statistical calculations. Out of the total 441 ALK-positive patients, 97 (21.9%) had ECOG PS 2-4 (poor PS). The median PFS was 9.3 months (95% CI = 6.6-12.0) as compared to 14.9 months (95% CI = 13.4-16.4) for patients with a PS of 0-1 (HR = 1.38, 95% CI = 1.04-1.84, The ALK-rearranged NSCLC patients with poor PS derived significant benefits with ALK inhibitors. The outcomes were significantly poorer as compared to patients with PS 0-1; the subgroup of patients with PS 2 had better outcomes as compared to patients with PS 3-4.
Sections du résumé
Background
UNASSIGNED
Anaplastic lymphoma kinase (ALK) inhibitors have shown significant efficacy in ALK -rearranged non-small cell lung cancer (NSCLC) patients with good performance status (PS) in multiple randomised studies. However, there is limited data on patients with poor performance status.
Patients and methods
UNASSIGNED
We carried out a retrospective analysis of prospectively collected data of patients with ALK-rearranged NSCLC and Eastern Cooperative Oncology Group (ECOG) PS of 2-4 treated at a single academic cancer centre from January 2013 to November 2018. The outcomes, progression-free survival (PFS) and overall survival (OS) were calculated from the date of diagnosis. SPSS version 20 was used for all statistical calculations.
Results
UNASSIGNED
Out of the total 441 ALK-positive patients, 97 (21.9%) had ECOG PS 2-4 (poor PS). The median PFS was 9.3 months (95% CI = 6.6-12.0) as compared to 14.9 months (95% CI = 13.4-16.4) for patients with a PS of 0-1 (HR = 1.38, 95% CI = 1.04-1.84,
Conclusion
UNASSIGNED
The ALK-rearranged NSCLC patients with poor PS derived significant benefits with ALK inhibitors. The outcomes were significantly poorer as compared to patients with PS 0-1; the subgroup of patients with PS 2 had better outcomes as compared to patients with PS 3-4.
Identifiants
pubmed: 36072236
doi: 10.3332/ecancer.2022.1407
pii: can-16-1407
pmc: PMC9377804
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1407Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Natl Compr Canc Netw. 2021 Mar 02;19(3):254-266
pubmed: 33668021
Ann Oncol. 2020 Aug;31(8):1056-1064
pubmed: 32418886
J Thorac Oncol. 2008 Feb;3(2):125-9
pubmed: 18303431
J Thorac Oncol. 2011 Sep;6(9):1474-80
pubmed: 21642865
J Clin Oncol. 2013 Aug 10;31(23):2849-53
pubmed: 23775961
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
Lung Cancer. 2014 Feb;83(2):259-64
pubmed: 24300132
N Engl J Med. 2018 Nov 22;379(21):2027-2039
pubmed: 30280657
Lancet. 2017 Jul 1;390(10089):29-39
pubmed: 28501140
J Thorac Oncol. 2011 Apr;6(4):774-80
pubmed: 21336183
Ann Oncol. 2013 Jan;24(1):59-66
pubmed: 22887466
Lancet Oncol. 2012 Nov;13(11):1161-70
pubmed: 23078958
J Thorac Oncol. 2017 Jul;12(7):1161-1166
pubmed: 28238961
PLoS One. 2016 Sep 16;11(9):e0160752
pubmed: 27637025
Oncotarget. 2019 May 3;10(33):3093-3103
pubmed: 31139322
J Clin Oncol. 2018 Aug 1;36(22):2251-2258
pubmed: 29768118
Lancet. 2017 Mar 4;389(10072):917-929
pubmed: 28126333